Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Depreciation & Amortization (CF) (2016 - 2025)

Jaguar Health (JAGX) has disclosed Depreciation & Amortization (CF) for 10 consecutive years, with $479000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 1.05% to $479000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.9 million, a 0.52% decrease, with the full-year FY2024 number at $1.9 million, down 5.61% from a year prior.
  • Depreciation & Amortization (CF) was $479000.0 for Q3 2025 at Jaguar Health, roughly flat from $478000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $558000.0 in Q2 2022 to a low of $426000.0 in Q1 2022.
  • A 5-year average of $476263.2 and a median of $479000.0 in 2025 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): grew 29.77% in 2022, then decreased 11.13% in 2024.
  • Jaguar Health's Depreciation & Amortization (CF) stood at $429000.0 in 2021, then increased by 16.32% to $499000.0 in 2022, then rose by 0.6% to $502000.0 in 2023, then decreased by 4.78% to $478000.0 in 2024, then increased by 0.21% to $479000.0 in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Depreciation & Amortization (CF) are $479000.0 (Q3 2025), $478000.0 (Q2 2025), and $479000.0 (Q1 2025).